AbbVie to Report Q2 Earnings Before July 31, With Potential for Post-Earnings Volatility
Before the market opens on July 31, AbbVie is set to report its second-quarter earnings. The company has been building momentum following a strong first-quarter performance driven by growth in immunology treatments like Rinvoq and Skyrizi. Analysts expect quarterly earnings of around $3.61 per share, representing a 21.5% increase year-over-year. Despite this positive outlook, AbbVie recently warned about the impact of one-time charges on its upcoming results. Shares have continued to rise despite these warnings, but investors should be cautious as post-earnings volatility is possible regardless of whether earnings meet or exceed expectations. The company's pending $10.9 billion acquisition of Apogee Therapeutics also adds strategic momentum. For long-term investors, the focus remains on AbbVie’s immunology pivot and its 2.7% forward dividend yield. A post-earnings pullback could offer a favorable entry point for new buyers.
Tickers: $ABBV
Topics: acquisitions immunology drugs patent exclusivity pharmaceuticals